Chinese VC Firm Decheng Capital Backs $14M Series A Round Of Biotech Start-Up

Chinese biotechnology start-up AnHeart Therapeutics announced on Wednesday that it has raised approximately RMB100 million (US$14.54 million) in a series A round of financing from the country’s venture capital firm Decheng Capital.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

LEAVE A REPLY